She	eet	1	of 1	·	OIPE				
INF	ORI		TION DISCLOSU CITATION	RE 620-34		10/516,338			
	(Use	sev	eral sheets if necessary)	COSM	E ET AL	GROUP		<del></del>	<del></del>
					nber 30, 2004	1645			<u> </u>
"EXA	MINER		<del></del>	0.8.	PATENT DOCUMENTS			FILING	DATE
	IAL	r	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	IF APPRO	PRIATE
		-					_		
		-							
		-							
		L	×						<u>-</u>
		-							
		$\vdash$		<del>  -</del>		<del></del>			
		╁╴	· · · · · · · · · · · · · · · · · · ·					<del>                                     </del>	
				FORE	IGN PATENT DOCUMENT	rs			
			DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSI YES	NO NO
		_							
		<u> </u>		-	·				<del></del>
		├			·			<del> </del>	
-		╁		<del> </del>					
		<u> </u>	OTHER DOCUM	ENTS (incl	uding Author, Title, Date	, Pertinent pa	iges, etc.	.)	
	AK	67	Shimizu et al J. of	Inorganic I	Biochemistry 81 (2000) 191	1-205			
	<u> </u>								
	<u> </u>	<u> </u>			<del> </del>				
	<b> </b>						·		
	<u> </u>	├		<del></del>	····		· .		
		-		<del></del>					•
		┝							•
		一							
	$\vdash$	$\vdash$							•
*Examir			Mi		Date Considered	1 (/2	4107		
Examin copy of	er: Initi this for	el if r n wit	eference considered, whether on the next communication to applic	r not citation is in cation.	conformance with MPEP 609; Draw line throug	gh citation if not in confo	rmance and not	considered.	Include

1112496

# Sheet 1 of

INFORI	MATION DISCLOS	IRE ATTY, DOCKET NO.		SERIAL NO.			
	CITATION	620-347	10/516,338	/516,338			
		APPLICANT					
		COSME ET AL				,	
(Use	several sheets if necessary)	FILING DATE	GROUP				
·		November 30,	2004	1645			
			T DOCUMENTS	1040			
*EXAMINER		U.S. PATEN	I DOCUMENTS			FILING DATE	
INITIAL	DOCUMENT NUMBER	DATE .	NAME	CLASS	SUBCLASS	IF APPROPRIATE	
				·			
				·			
·		,					
		<u> </u>					
	,	<del> </del>					
		<del> </del>					
	<u> </u>	FOREIGN DA	TENT DOOLINE	LTO.			
		FOREIGN PA	TENT DOCUMEN	VIS		TRANSLATION	
	DOCUMENT	DATE	COUNTRY	. CLASS	SUBCLASS	YES NO	
	T T	T			T	<del></del>	
		<u> </u>					
					<u> </u>	· · · · ·	
	<del></del>						
	OTHER DOCUM	MENTS (including A	Author Title Dat	Partinent na	nas etc	\	
AK	1 Roddupalli et al	Proc. Natl. Acad. Sc	i 1992 Val 89	nn 5567-5571	ages, etc.	<u> </u>	
An	2 Obayashi et al.	ournal of Inorganic E	Riochemistry 82 (	2000) 103-111	••••		
<del></del>		mistry 2001, 40, 134					
<del>- -</del>		Chem. Soc. 2003, 1		<u> </u>			
<del>  -</del>							
$\vdash$	6 Doules The low	st. (1995), D51, 21-3 nal of Biological Che	omistry 1082 Vo	1 257 No. 17	10427-10	120	
<u> </u>				1. 237, NO. 17,	10421-10	423	
		emistry 1991, 30, 1					
1/		iochem. 2000, 128,		n 0211 0210			
<u> </u>	9 vidaković et al, E	Biochemistry, 1998, \	νοι. 37, Νο. 26, <u>ρ</u>	p 9211-9219		<del></del>	
			·				
*Examiner	1 00 -		Date Considere	d	11 12 17	<del></del>	
	al if reference considered whether	or not citation is in conformance v		172	rmance and not	considered. Include	
copy of this for	n with next communication to app	ication.	THE TAX ET COO, DIAW MIE BITC			ASSO (AL- DTO 4440)	

# Sheet 1 of 1

INF	INFORMATION DISCLOSURE			RE ATTY. D	E ATTY, DOCKET NO. SERIAL NO.					
	,		CITATION	620-3	347	10/516,338	16.338			
				APPLIC		,				
				COSI	ME ET AL					
	(Use	sev	eral sheets if necessary)	FILING		GROUP			<del></del>	
				Nove	mber 30, 2004	1645				
	•				3. PATENT DOCUMENTS	1010	<del> </del>			
*EXAN	MINER	_		0.5	S. FAILNI DOCUMENTS			FILING	DATE	
רוחו			DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	IF APPRO	OPRIATE	
_		L						ļ		
		<u> </u>		_			<b>.</b>	ļ	<del> </del>	
		_			·			<del></del>		
		_					<del> </del>			
	<del></del>	<u> </u>					<del> </del>	$\vdash$	<del></del>	
		┝				<del>  </del>	<del></del>	<del> </del>		
		<del> </del>								
		-								
			,							
		-								
		$\vdash$					<del></del>			
				· · · · · · · · · · · · · · · · · · ·			<del></del>	_		
		$\vdash$								
-										
				·						
				FOR	EIGN PATENT DOCUMEN	TS				
							-		LATION	
			DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO	
	K		WO 2004/038015		WIPO			<u> </u>		
	<b>4</b> 6	2	WO 2004/038655	05/2004	WIPO.			<u> </u>	<u> </u>	
	· · · · · · · · · · · · · · · · · · ·	L						<u> </u>	ļ	
					·				ļ	
		L						<del></del>	<b>_</b>	
		<u> </u>					ļ <del> </del>	<del></del>	<b>-</b>	
		_	•				<u> </u>	<u> </u>	<del> </del>	
		L_	OTUED DOOLING	ENTO (5	, , , , , , , , , , , , , , , , , , ,	- D4in4		<del></del>	<u> </u>	
	11.	2			cluding Author, Title, Date		iges, etc.	<u>}</u>		
	ALL				al Biology (2003), 142(1), 1		(2).506 6(	10		
	$\vdash \vdash$	_			Function, and Bioinforma	iius (2005), 361	(J).580-0L	<u>.</u>		
,	$\vdash \vdash$				v. (2004), 33(8), 558-565	2005 issued in	- consoct	ion with	<del></del>	
	<u>\</u>		PCT/GB2005/0010		Report dated November 2,	2005 issued if	Connect	On Will	· · · · · · · · · · · · · · · · · · ·	
	L	L_			· · · · · · · · · · · · · · · · · · ·		-6.6.5		·	
*Examir			Stein		Date Considered	1/2	4/09			
			eference considered, whether o		conformance with MPEP 609; Draw line through	ugn citation if not in confo	rmance and not	considered	. include	

Fare	MA	TION DISCLOSU	RE ATTY. I	DOCKET NO.	SERI	AL NO.			
170	, J	NOITATES	620-3	620-347 10/516,338					
	~00	ار بر الا	APPLIC	ANT					
INH S B	, m			ME ET AL					
			FICING	DATE	GRO	UP			
(Use	ADE	Mr.	Nove	mber 30, 2004	164	5			
			U.S	. PATENT DOCL	IMENTS				
MINER ITIAL		DOCUMENT NUMBER	DATE	NAN	ΛE	CLASS	SUBCLASS		DATE OPRIATE
TIAL	Т	DOGGINETT WORLDETT	<u> </u>		····			Γ	
	$\vdash$						•		
	$\top$								
	$\top$								
								<u> </u>	
						<u> </u>		<u></u>	
			FOR	EIGN PATENT D	OCUMENTS			70	LATION
7				2017	ITDV	CLASS	CHRCLACE	YES	ILATION NO
		DOCUMENT	DATE	COUN	IIHY	CLASS	SUBCLASS	1	, NO
	<u> </u>					<del></del>		<del> </del>	<b> </b>
	$\perp$					<del></del>			ļ
	↓_				·			<del> </del>	
	<u> </u>					<del></del>	ļ	<del> </del>	
	╄					<del></del>			<del> </del>
	<u></u>	OTHER DOCUM	ENTS (in	oluding Author	Title Date Per	inent n	anes etc	1	l
	Τ-	Longenecker KL et	al · Acta C	rystallogr D Biol Cr	vstallogr 2001 5	7(Pt 5), 6	79-88	·/	
ALL	╀	Mansuy, Daniel; Un				. (), .			_
	1	Abstract 5. Origin	of Substra	te Specificity of C	viochromes P45	0.2C: Ch	<del>iemical a</del> n	d	Vat
	Τ	Biochemical Appro	oaches.	•					miss
AK	Т	Marques-Soares, C	. et al; Bio	chemistry ; <b>2003</b> ; 4.	<i>2</i> (21); 6363-6369				
		Ravichandran K G				ust 1993			
		Schoch GA et al; J			10): 9497-9503.				
$\square$		Sevrioukova et al.;							
	L	Sueyoshi et al.; Arc	hives of Bi	ochemistry and Bio	physics; Vol. 322	, No. 1, 1	995, pp 26	55-271	
	Ĺ	Szklarz GD; J. Com					·		
		Wester, M. R.; Bioc							
Wester, M. R.; et al.; Biochemistry; 2003; 42(21); 6370-6379.							104		
لبلبا	1	Zamora, I.; Afzelius	, L.; Crucia	ni, G.; <i>J. Med. Che</i>	m.; <b>2003</b> ; <i>46</i> (12)	2313-23	24.		
V	+-	Zamora, Isobel; Lead Molecular Design, S.L. Sant Cugat del Valles, Spain.							
V		101		sm-kte <del>aiction tot</del>	<del>cytochrome P4.</del>	,		7000	,
<b>▼</b>	L	Abstract/Poster 77.	wetabon						
<b>V</b>		Abstract/Poster 77.	-wetabon						
		Abstract/Poster 77.	- wietaboii:						-
		Abstract/Poster 77.	·						
Niner		Abstract/Poster 77.	·		Date Considered		1/10	7	

	ATION DISCLOSU	RE ATTY. DO	OCKET NO. SE	FRIAL NO.			
INFORMATION DISCLOSE		620-34	47	0/516,338			
,	<b>&amp;</b> \	APPLICA	INI				
Ann.	씽	_	1E ET AL				
W. J. Dise se	everal sheets if necessary)	FILING	ATE GI	ROUP			
ند.	<b>\$</b>	Noven	nber 30, 2004 10	645			
78 TRAUEN	<b>/</b>	U.S.	PATENT DOCUMENTS				·
XAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING IF APPRO	
AK	6,312,917	11/2001	Thakker et al.		I		
AK	6,432,639	08/2002	Lichter et al.			<u>.</u>	
			<u>·</u>		ļ <u> </u>		<del>_</del>
					l	<u> </u>	·
		FORE	IGN PATENT DOCUMENTS			TRANSI	ATION
	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO
AK	DE 195 49 267	07/1997	Germany				<del></del>
AK	WO 99/08812	02/1999	WIPO				
	110 00/00012	02 1000					
		<u> </u>			<u></u>	Ļl	
	OTHER DOCUM	ENTS (inc	luding Author, Title, Date, Pe	ertinent pa	ges, etc.	.)	2002
14	Armelle Melet et al.	ENTS (inc ; Archives o	luding Author, Title, Date, Performed Biochemistry and Biophysics, V	ertinent pa folume 409,	ges, etc. Issue 1, 1	) Januar	y 2003,
AK	Armelle Melet et al. Pages 80-91.	; Archives o	of Biochemistry and Biophysics, V	olume 409,	ges, etc. Issue 1, 1	) Januar	y 2003,
AK	Armelle Melet et al. Pages 80-91. Cheng-Chung Tsac	; Archives o	of Biochemistry and Biophysics, Volumental Hernistry; <b>2001</b> ; 40(7), 1937 – 19	olume 409, 44	l ages, etc. Issue 1, 1	Januar	
<del></del>	Armelle Melet et al. Pages 80-91. Cheng-Chung Tsac Dansette, Patrick M Abstract/Poster 81	; Archives o et al.; Bioc l.; Universite Sulphena	of Biochemistry and Biophysics, Volumentally, 2001; 40(7), 1937 – 1909 Rene Descartes, Paris, France.  Toole Derivatives as Tools for Communications.	olume 409, 44  omparing (	SYP 2C5 a	Januar nd Hun	nan D
<del></del>	Armelle Melet et al. Pages 80-91. Cheng-Chung Tsac Dansette, Patrick M Abstract/Poster 81	; Archives o et al.; Bioc l.; Universite Sulphena	of Biochemistry and Biophysics, Volumental Hernistry; <b>2001</b> ; 40(7), 1937 – 19	olume 409, 44  omparing (	SYP 2C5 a	Januar nd Hun	
<del></del>	Armelle Melet et al. Pages 80-91. Cheng-Chung Tsac Dansette, Patrick MAbstract/Poster 81. 2C's: Identification Enzymes.	et al.; Bioc. L.; Universite Sulphena n of a New	hemistry; 2001; 40(7), 1937 – 19 e Rene Descartes, Paris, France. zole Derivatives as Tools for Go High Affinity Substrate (DMZ) C	olume 409, 44  omparing (	SYP 2C5 a	Januar nd Hun	nan D
<del></del>	Armelle Melet et al. Pages 80-91. Cheng-Chung Tsac Dansette, Patrick M Abstract/Poster 81. 2C's: Identification Enzymes. Ekins, S. et al.; J. F.	et al.; Biocol.; Universite Sulphenan of a New	the Biochemistry and Biophysics, Verbemistry; 2001; 40(7), 1937 – 1909; Pene Descartes, Paris, France. Tools for Company of the Affinity Substrate (DMZ) Company of the Exp Ther.; 1999; 290(1); 429-38	olume 409, 44  omparing (	SYP 2C5 a	Januar nd Hun	nan D
<del></del>	Armelle Melet et al. Pages 80-91. Cheng-Chung Tsac Dansette, Patrick M Abstract/Poster 81. 2C's: Identification Enzymes. Ekins, S. et al.; J. F. Ekins, S. et al.; J. F.	et al.; Bioca d.; Universite Sulphena n of a New Pharmacol. E Pharmacol. E	the Biochemistry and Biophysics, Venemistry; 2001; 40(7), 1937 – 1909; Rene Descartes, Paris, France. Tools for Company and Affinity Substrate (DMZ) Company (DMZ)	olume 409, 44  comparing (Common to	SYP 2C5 a	Januar nd Hun	nan D
<del></del>	Armelle Melet et al. Pages 80-91. Cheng-Chung Tsac Dansette, Patrick M Abstract/Poster 81. 2C's: Identification Enzymes. Ekins, S. et al.; J. F. Guengerich, F.P. et	et al.; Bioca L; Universite Sulphena n of a New l Pharmacol. E hal.; Annu. F	themistry; 2001; 40(7), 1937 – 1949; 2001; 40(7), 1937 – 1949; 2019; 40(7), 1937 – 1949; 2019; 400; 400; 400; 400; 400; 400; 400; 40	olume 409, 44  comparing (Common to	SYP 2C5 a	Januar nd Hun	nan D
<del></del>	Armelle Melet et al. Pages 80-91. Cheng-Chung Tsac Dansette, Patrick M Abstract/Poster 81. 2C's: Identification Enzymes. Ekins, S. et al.; J. F. Ekins, S. et al.; J. F. Guengerich, F.P. et He M et al.; Arch B.	et al.; Bioco l.; Universite Sulphena n of a New I Pharmacol. E Pharmacol. E d al.; Annu. F iochem Biop	themistry; 2001; 40(7), 1937 – 1949; Rene Descartes, Paris, France. Tools for Country and Affinity Substrate (DMZ) Country Ther.; 1999; 290(1); 429-38; Exp Ther.; 1999; 291(1); 424-33; Rev. Pharmacol. Toxicol.; 1999; 30 (1); 1999; 20(1); 1999; 30 (1); 1999; 20(1); 1999; 30 (1); 1999; 20(1); 1999; 30 (1); 1999; 1999; 1999; 1999; 1999; 1999; 1999; 1999; 1999; 1999; 1999; 1999; 1999; 1999; 1999; 1999; 1999; 1999; 1999; 19	olume 409, 44  comparing (Common to	SYP 2C5 a	Januar nd Hun	nan D
<del></del>	Armelle Melet et al. Pages 80-91. Cheng-Chung Tsac Dansette, Patrick M Abstract/Poster 81. 2C's: Identification Enzymes. Ekins, S. et al.; J. F. Guengerich, F.P. et He M et al.; Arch B. Hosea NA et al.; Bi	et al.; Bioca l.; Universite Sulphena n of a New Pharmacol. Et al.; Annu. R iochem Biop ochemistry;	themistry; 2001; 40(7), 1937 – 1949; Rene Descartes, Paris, France. Tole Derivatives as Tools for General High Affinity Substrate (DMZ) CEXP Ther.; 1999; 290(1); 429-38 (EXP Ther.; 1999; 291(1); 424-33 (EXP Ther.; 1999; 291(1); 429-34 (EXP Ther.; 1999; 291(1); 429	olume 409, 44 comparing (Common to	CYP 2C5 a Those C	Januar nd Hun	nan D
<del></del>	Armelle Melet et al. Pages 80-91. Cheng-Chung Tsac Dansette, Patrick MAbstract/Poster 81. 2C's: Identification Enzymes. Ekins, S. et al.; J. F. Ekins, S. et al.; J. F. Guengerich, F.P. et He M et al.; Arch B. Hosea NA et al.; Bi Hutzler, J.M. et al.;	et al.; Bioca l.; Universite Sulphena n of a New land Pharmacol. Et al.; Annu. H iochem Biop ochemistry; Archives of	themistry; 2001; 40(7), 1937 – 1949; Rene Descartes, Paris, France. Tole Derivatives as Tools for Got High Affinity Substrate (DMZ) Company Ther.; 1999; 290(1); 429-38 Exp Ther.; 1999; 291(1); 424-33 Exp Ther.; 1999; 291(1); 424-33 Exp Ther.; 1999 Dec 1;372(1):16-28.	olume 409, 44 comparing (Common to	CYP 2C5 a Those C	Januar nd Hun	nan D
<del></del>	Armelle Melet et al. Pages 80-91. Cheng-Chung Tsac Dansette, Patrick M Abstract/Poster 81. 2C's: Identification Enzymes. Ekins, S. et al.; J. F. Guengerich, F.P. et He M et al.; Arch Bi Hutzler, J.M. et al.; Hutzler, J.M. et al.;	et al.; Bioc. L.; Universite Sulphena n of a New Pharmacol. Et al.; Annu. R iochem Biop ochemistry; Archives of Drug Metab	themistry; 2001; 40(7), 1937 – 1949; Rene Descartes, Paris, France. Tole Derivatives as Tools for Got High Affinity Substrate (DMZ) Company Ther.; 1999; 290(1); 429-38 Exp Ther.; 1999; 291(1); 424-33	olume 409, 44  comparing Common to 39; 1-17	-24.	Januar nd Hun	nan D
<del></del>	Armelle Melet et al. Pages 80-91. Cheng-Chung Tsac Dansette, Patrick Mabstract/Poster 81. 2C's: Identification Enzymes. Ekins, S. et al.; J. F. Guengerich, F.P. et He M et al.; Arch B. Hosea NA et al.; Bi Hutzler, J.M. et al.; Hutzler, J.M. et al.; Hutzler, J.M. et al.;	et al.; Bioco l.; Université Sulphena n of a New l Pharmacol. Et al.; Annu. Priochem Biop ochemistry; Archives of Drug Metabo	themistry; 2001; 40(7), 1937 – 1949; Rene Descartes, Paris, France. Tole Derivatives as Tools for County Ther.; 1999; 290(1); 429-38. Exp Ther.; 1999; 291(1); 424-33. Exp Ther.; 1999; 291(1); 424-33	omparing (Common to 39; 1-17)  03, 410, 16 30, pp 1194 29, 1029-10	-24. 4-1200.	nd Hun YP 2C	nan (m
<del></del>	Armelle Melet et al. Pages 80-91. Cheng-Chung Tsac Dansette, Patrick Mabstract/Poster 81. 2C's: Identification Enzymes. Ekins, S. et al.; J. F. Guengerich, F.P. et He M et al.; Arch B. Hosea NA et al.; Bi Hutzler, J.M. et al.; Hutzler, J.M. et al.; Hutzler, J.M. et al.;	et al.; Bioco l.; Université Sulphena n of a New l Pharmacol. Et al.; Annu. Priochem Biop ochemistry; Archives of Drug Metabo	themistry; 2001; 40(7), 1937 – 1949; Rene Descartes, Paris, France. Tole Derivatives as Tools for County Ther.; 1999; 290(1); 429-38. Exp Ther.; 1999; 291(1); 424-33. Exp Ther.; 1999; 291(1); 424-33	omparing (Common to 39; 1-17)  03, 410, 16 30, pp 1194 29, 1029-10	-24. 4-1200.	nd Hun YP 2C	nan (m
<del></del>	Armelle Melet et al. Pages 80-91. Cheng-Chung Tsac Dansette, Patrick Mabstract/Poster 81. 2C's: Identification Enzymes. Ekins, S. et al.; J. F. Ekins, S. et al.; J. F. Guengerich, F.P. et He M et al.; Arch B. Hosea NA et al.; Bi Hutzler, J.M. et al.; Hutzler, J.M. et al.; Johnson, Eric; Scrij Abstract 4. Structi	et al.; Bioca l.; Université Sulphena n of a New la Pharmacol. Et la al.; Annu. H iochem Biop ochemistry; Archives of Drug Metabo pps Researca ural Charac	themistry; 2001; 40(7), 1937 – 1949; Rene Descartes, Paris, France. Tole Derivatives as Tools for General High Affinity Substrate (DMZ) Company (DMZ)	omparing (Common to 39; 1-17)  03, 410, 16 30, pp 1194 29, 1029-10	-24. 4-1200.	nd Hun YP 2C	nan (m
<del></del>	Armelle Melet et al. Pages 80-91. Cheng-Chung Tsac Dansette, Patrick Mabstract/Poster 81. 2C's: Identification Enzymes. Ekins, S. et al.; J. F. Guengerich, F.P. et He M et al.; Arch Bi. Hutzler, J.M. et al.; Hutzler, J.M. et al.; Hutzler, J.M. et al.; Johnson, Eric; Scrij Abstract 4. Structu Kaminsky LS, Zhan	et al.; Bioc. L; Universite Sulphenan of a New Pharmacol. Et al.; Annu. R iochem Biopochemistry; Archives of Drug Metabo ops Research g ZY.; Phar	themistry; 2001; 40(7), 1937 – 1949; Rene Descartes, Paris, France. Tole Derivatives as Tools for County Ther.; 1999; 290(1); 429-38. Exp Ther.; 1999; 291(1); 424-33. Exp Ther.; 1999; 291(1); 424-33	omparing (Common to 39; 1-17)  03, 410, 16 30, pp 1194 29, 1029-10	-24. 4-1200.	nd Hun YP 2C	nan (m
<del></del>	Armelle Melet et al. Pages 80-91. Cheng-Chung Tsac Dansette, Patrick Mabstract/Poster 81. 2C's: Identification Enzymes. Ekins, S. et al.; J. F. Guengerich, F.P. et He M et al.; Arch B. Hutzler, J.M. et al.; Hutzler, J.M. et al.; Hutzler, J.M. et al.; Johnson, Eric; Scrij Abstract 4. Structu Kaminsky LS, Zhan Korzekwa, K.R et al.	et al.; Bioco bet al.; Bioco control of a New land control of a New land control of a New land control of a New land control of a New land land of a New land control of a New land land of a New land control of a New land	themistry; 2001; 40(7), 1937 – 1969; Rene Descartes, Paris, France. Tole Derivatives as Tools for General High Affinity Substrate (DMZ) Company (DMZ)	omparing (Common to 39; 1-17)  03, 410, 16 30, pp 1194 29, 1029-10	-24. 4-1200.	nd Hun YP 2C	nan (m
<del></del>	Armelle Melet et al. Pages 80-91. Cheng-Chung Tsac Dansette, Patrick Mabstract/Poster 81. 2C's: Identification Enzymes. Ekins, S. et al.; J. F. Ekins, S. et al.; J. F. Guengerich, F.P. et He M et al.; Arch B. Hosea NA et al.; Bi Hutzler, J.M. et al.; Hutzler, J.M. et al.; Johnson, Eric; Scrij Abstract 4. Structu Kaminsky LS, Zhan Korzekwa, K.R et al.; Muze KL et al.; Dr.	et al.; Bioco l.; Université Sulphena n of a New la Pharmacol. Et Pharmacol. Et al.; Annu. H iochem Biop ochemistry, Archives of Drug Metab Ops Research Iral Charac Ing ZY.; Phari ug Metab Di	themistry; 2001; 40(7), 1937 – 1949; Rene Descartes, Paris, France. Tole Derivatives as Tools for Get High Affinity Substrate (DMZ) Company Ther.; 1999; 290(1); 429-38 Exp Ther.; 1999; 291(1); 424-33 Rev. Pharmacol. Toxicol.; 1999; 30(1); 424-33 Rev. P	omparing (Common to 39; 1-17)  03, 410, 16 30, pp 1194 29, 1029-10	-24. 4-1200.	nd Hun YP 2C	nan (m
AK AK AK AKA AKA AKA AKA AKA AKA AKA AK	Armelle Melet et al. Pages 80-91. Cheng-Chung Tsac Dansette, Patrick Mabstract/Poster 81. 2C's: Identification Enzymes. Ekins, S. et al.; J. F. Ekins, S. et al.; J. F. Guengerich, F.P. et He M et al.; Arch B. Hosea NA et al.; Bit Hutzler, J.M. et al.; Hutzler, J.M. et al.; Hutzler, J.M. et al.; Johnson, Eric; Scrip Abstract 4. Structus Kaminsky LS, Zhan Korzekwa, K.R et al. Kunze KL et al.; Dr. Lewis, DF et al.; Xen Dr. Communication of the supplementation of the supplementatio	et al.; Bioca l.; Universite Sulphena n of a New land Pharmacol. Et Pharmacol. Et al.; Annu. Hi iochem Biop ochemistry; Archives of Drug Metabo Drug Metabo Drug Metabo ural Charac ing ZY.; Phar l.; Biochemia up Metab Di enobiotica; 1	themistry; 2001; 40(7), 1937 – 1949; Rene Descartes, Paris, France. Tole Derivatives as Tools for Get High Affinity Substrate (DMZ) Company (DMZ) (DMZ	olume 409, 44  comparing (Common to 39; 1-17  03, 410, 16 30, pp 1194 29, 1029-10  ibitor Bind	-24. 4-1200.	nd Hun YP 2C	nan (m

Sheet	t 1	of 4						
INFO	RMA	TION DISCLOSU	RE ATTY.	OCKET NO.	SERIAL NO.			
		CITATION	620-3 APPLIC		10/516,338	<u>:</u>		
			COSI	ME ET AL				
. (۱	Jse se	veral sheets if necessary)	FILING	DATE	GROUP		<del></del>	
			Nove	mber 30, 2004	Unassigned			
			U.S	. PATENT DOCUMENTS				
*EXAMINE		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS		DATE OPRIATE
1SIK		5,786,191	07/1998	Goldstein et al.				
1	-	5,834,250	11/1998	Wells et al.				
-		5,886,157	03/1999	Guengerich et al.				
<del></del>	-	5,912,120	06/1999	Goldstein et al.				
-	_	6,080,568	06/2000	Day et al.				
-		6,136,553	10/2000	Christianson et al.				
	<del>/    </del>	6,162,613	12/2000	Su et al.				
A		2003/0170842	09/2003	Williams et al				
							<u> </u>	
			FORI	EIGN PATENT DOCUMENTS	<u> </u>		701110	LATION
		DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO NO
AK		WO 98/02554	01/1998	WIPO			ļ <u> </u>	<u> </u>
1		WO 01/11035	02/2001	WIPO			ļ	<u> </u>
		WO 01/14565	03/2001	WIPO			<u> </u>	ļ
		WO 03/035693 A	05/2003	WIPO			<u> </u>	ļ
		WO 03/040994 A		WIPO			ļ	<u> </u>
			12/2003	WIPO		<u></u>	Ļ	J
		OTHER DOCUM	ENTS (inc	cluding Author, Title, Date, I	Pertinent pa	iges, etc.	.)	lo Dimor
1/4	He	in E. coli Following Mod	ifications of It	Cosme, J. and Johnson, E.; Microsoms N-terminus, Archives of Biochemistry	and Biophysics,	1997, Vol. 3	39, No. 1	1, pp.
		Cosme, J. and Johnson	, E.; Enginee	ring Microsomal Cytochrome P450 2C5	to Be a Soluble	Monomeric	Enzyme,	Journal
-	1	Williams P : Cosme J .:	Sridhar, V.:	75, No. 4, pp. 2545-2553. Johnson, E. and McRee, D.; Mammalia	n Microsomal Cy	tochrome P4	<del>450</del>	
		Monooxygenase: Struct	ural Adaptation	ons for Membrane Binding and Function	nal Diversity, Mo	lecular Cell,	2000, VO	
		Williams, P.; Cosme, J.;	Sridhar, V.;	Johnson, E. and McRee, D.; Microsoma , <i>Joumal of Inorganic Biochemistry</i> , <b>200</b>	al cytochrome P4 00 Vol. 81, pp18	l50 2С5: соп 3-190.	iparison (	of
-	++-	IT H Richardson F Jun	ng, K. J. Griffi	n. M. Wester, J. L. Raucy, B. Kemper, I	L. M. Bornheim, (	C. Hassett, C	J. J. Omi	ecinski
	1	and E. F. Johnson: A U	niversal Appre	oach to the Expression of Human and F	Rabbit Cytochron	ne P450s of	the 2C S	ubfamily
_	₩	in Escherichia coli; Arch	voression S	emistry and Biophysics, 1995, Volume stem Of Modified Substance Of Ctochro	ome P450 2c19	In Escherich	ia Coli; Ir	nventor:
	11	Baba Takahiko; Kirita S	hiro; Aoyama	Junko; Assignee: Shionogi & Co Ltd; F	iled: July 23, 19	96. Filed to	gether w	ith .
<u> </u>	Ш.	English abstract.			_			
		hydroxylase in Escheric	hia coli: Proc	R; Expression and enzymatic activity of . <i>Natl. acad. Sci. USA</i> ; <b>1991</b> , 88, 5597-5	5601.			•
		Kempf AC, Zanger UM,	Mever UA: T	runcated human P450 2D6: expression olubility and aggregation; Arch. Biocher	in Escherichia c	:oli, Ni(2+)-cl 5, 321, 277-:	nelate aff 28 <u>8.</u>	inity
	1	Gillam EM, Guo Z, Mart	in MV. Jenkir	ns CM, Guengerich FP; Expression of concentrations of concentrations of the concentration of	ytochrome P450	2D6 in Esch	rerichia c	oli,
*Examiner	- 1	1 du	<del></del>	Date Considered	1/24	107		
				conformance with MPEP 609; Draw line through	citation if not in confo	rmance and not	considered	l. Include
copy of this	torm w	th next communication to applic	ation.			Form PTO-FR	-A820 (Also	PTO-1449

## Sheet 2

#### INFORMATION DISCLOSUR TTY. DOCKET NO.

SERIAL NO.

10/516,338

**CITATION** 

620-347

APPLICANT

(Use several sheets if necessary)

**COSME ET AL** 

FILING DATE

GROUP

November 30, 2004

Unassigned

'EXAMINER	OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)
AB	Pernecky SJ, Larson JR, Philpot RM, Coon MJ; Expression of truncated forms of liver microsomal P450 cytochromes 2B4 and 2E1 in Escherichia coli: influence of NH2-terminal region on localization in cytosol and membranes; <i>Proc. Natl. Acad. Sci. USA</i> , 1993, 90, 2651-2655.
	JR Larson, MJ Coon, and TD Porter; Alcohol-inducible cytochrome P-450IIE1 lacking the hydrophobic NH2- terminal segment retains catalytic activity and is membrane-bound when expressed in Escherichia coli; <i>J. Biol. Chem</i> , 1991, 266, 7321-7324
$\neg$	Sagara Y., Barnes H. J. and Waterman M. R.; Expression in <i>Escherichia coli</i> of Functional Cytochrome P450 <sub>c17</sub> Lacking Its Hydrophobic Amino-Terminal Signal Anchor, <i>Arch. Biochem. Biophys.</i> , <b>1993</b> , 304, 272-278.
	Gillam EM, Baba T, Kim BR, Ohmori S, Guengerich FP; Expression of modified human cytochrome P450 3A4 in Escherichia coli and purification and reconstitution of the enzyme; <i>Arch Biochem Biophys.</i> , 1993; 305(1); 123-31.
	Emily E. Scott, Margit Spatzenegger and James R. Halpert; A Truncation of 2B Subfamily Cytochromes P450 Yields Increased Expression Levels, Increased Solubility, and Decreased Aggregation While Retaining Function, <i>Arch. Biochem. Biophys.</i> , 2001, Volume 395, Issue 1, 57-68.
	Meehan, R.R., Gosden, J.R., Rout, D., Hastie, N.D., Friedberg, T., Adesnik, M., Buckland, R., van Heyningen, V., Fletcher, J.M., Spurr, N.K., Sweeney, J. and Wolf, C.R.; Human cytochrome P-450 PB-1: a multigene family involved in mephenytoin and steroid oxidations that maps to chromosome 10; Am. J. Hum. Genet.; 1988, 42 (1), 26-37.
	Kimura, S., Pastewka, J., Gelboin, H.V. and Gonzalez, F.J.; cDNA and amino acid sequences of two members of the human P450IIC gene subfamily: <i>Nucleic Acids Res.</i> ; <b>1987</b> , 15 (23), 10053-10054.
	Romkes, M., Faletto, M.B., Blaisdell, J.A., Raucy, J.L. and Goldstein, J.A.; Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily; <i>Biochemistry</i> ; 1991, 30 (13), 3247-3255.
	Gonzalez, F.J., Vilbois, F., Hardwick, J.P., McBride, O.W., Nebert, D.W., Gelboin, H.V. and Meyer, U.A.; Human debrisoquine 4-hydroxylase (P450IID1): cDNA and deduced amino acid sequence and assignment of the CYP2D locus to chromosome 22: Genomics, 1988, vol 2 (2), 174-179.
	Hasemann, C. A. et al., Crystal Structure and Refinement of Cytochrome P450terp at 2.3 Å resolution J. Mol. Biol. 236(4) 1169-1185 (1994)
	Lewis, David F. V. et al., Homology Modelling of Human Cytochromes P450 involved in Xenobiotic Metabolism and Rationalization of Substrate Selectivity Experimental and Toxicologic Pathology 51(4-5) 369-374 (1999)
	Ibeanu GC, Ghanayem BI, Linko P, Li L, Pederson LG, Goldstein JA.; Identification of residues 99, 220, and 221 of human cytochrome P450 2C19 as key determinants of omeprazole activity; <i>J. Biol. Chem.</i> , 1996, Vol. 271, 12496-12501
	David R. Nelson et al., P450 Superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6 1-42 (1996).
	Nienaber et al., Re-engineering of Human Urokinase Provides a System for Structure-based Drug Design at High Resolution and Reveals a Novel Structural Subsite, J. Biol. Chem. 275(10) 7239-7248 (2000)
	Dale et al., Crystal Engineering: deletion mutagenesis of the 24 kDa fragment of the DNA gyrase B subunit from Staphylococcus aureus, Acta Crystallographica D55, 1626-1629 (1999)
	Wolfram Schiweck and Arne Skerra, The Rational Construction of an Antibody against Cystatin: Lessons from the crystal structure of an artificial Fab fragment, <i>J. Mol. Biol.</i> <b>268</b> 934-951 (1997)
	Stephen R. Price and Kiyoshi Nagai, Protein Engineering as a Tool for Crystalography, Current Opinion in Biotechnology 6 425-430 (1995)
	Lawson et al., Solving the Structure of Human H Ferritin by Genetically Engineering Intermolecular Crystal Contacts, Nature 349 541-544 (1991)
V	Park et al., Crystallization and preliminary X-ray diffraction analysis of a cytochrome P450 (CYP119) from Sulfolobus Solfataricus, Acta Crystallographica Section D Biological Crystallography, Vol. 56, No. 9, September 2000 (2000-09), pages 1173 - 1175
*Examiner	Date Considered 1/2/1/4/7

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Sheet	3	of	4
-------	---	----	---



# INFORMATION DISCLOSURE

ATTY. DOCKET NO.

SERIAL NO.

**CITATION** 

620-347

10/516,338

COSME ET AL

(Use several sheets if necessary)

GROUP

November 30, 2004

Unassigned

Ridderströr Biophysical Payne at al November	THER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)  n et al., Arginines 97 and 98 in CYP2C9 are important determinants of the catalytic function, Biochemical and Research Communications 270, 983-987 (2000)  ., Homology modelling and substrate binding study of human CYP2C9 enzyme, Proteins, vol. 37, no. 2, 1 1999, pages 176 - 190  .Pharmacophore and three-dimensional quantitative structure activity relationship methods for modeling
Payne at all	, Homology modelling and substrate binding study of human CYP2C9 enzyme, Proteins, vol. 37, no. 2, 1 1999, pages 176 - 190  Pharmacophore and three-dimensional quantitative structure activity relationship methods for modeling
Ekins et al	Pharmacophore and three-dimensional quantitative structure activity relationship methods for modeling
cvtochrome	P450 active sites. Drug Metabolism and Disposition, Vol. 29, No. 7, July 2001, pages 936-944
Stubbins et	al., Genetic analysis of the human cytochrome P450 CYP2C9 locus, Pharmacogenetics (1996) 6, 429 - 439
dimensiona 919	risa et al., Competitive CYP2C9 inhibitors: Enzyme inhibition studies, protein homology modeling, and three- I quantitative structure-activity reationship analysis, Molecular Pharmacology, April 2001; Vol. 59, no. 4: 909 –
Archives of	. V., Essential requirements for substrate binding affinity and selectivity toward human CYP2 family enzymes, Biochemistry and Biophysics; Vol. 409, no. 1 (2003), 32 - 44
Williams P 424(6947):	A et al., Crystal structure of human cytochrome P450 2C9 with bound warfarin, Nature, 2003, Jul. 24;
De Groot, Med. Chem	flarcel J et al., Development of a combined protein and pharmacophore model for cytochrome P450 2C9, J. 2002, Vol. 45, no. 10, 1983 - 1993
Blundell, T. Nature Pub Vol. 1, no.	L. et al., High throughput crystallography for lead discovery in drug design, Nature Reviews. Drug Discovery, lishing Group, Basingstoke, GB;
Pamela A. Vonrhein, I Progestero	Williams, Jose Cosme, Dijana Matak Vinkovic, Alison Ward, Hayley C. Angove, Philip J. Day, Clemens and J. Tickle, Harren Jhoti; Crystal structures of human cytochrome P450 3A4 bound to Metyrapone and the Science, 30 July <b>2004</b> ; 305; 683 - 686
Jason K. Y Structure o	ano, Michael R. Wester, Guillaume A. Schoch, Keith J. Griffin, C. David Stout and Eric F. Johnson; The Human Microsomal Cytochrome P450 3A4 Determined by X-Ray Crystallography to 2.05-Å Resolution, J. Biol. 2 2004; 279: 38091 - 38094
Gonzalez F sequence, DNA: 1988	J, Schmid BJ, Umeno M, Mcbride OW, Hardwick JP, Meyer UA, Gelboin HV, Idle JR; Human P450PCN1: chromosome localization, and direct evidence through cDNA expression that P450PCN1 is nifedipine oxidase, 7(2): 79 - 86
Beaune Pt	, Umbenhauer DR, Bork RW, Lloyd RS, Guengerich FP, Isolation and sequence determination of a cDNA clone uman cytochrome P-450 nifedipine oxidase, Proc. Natl. Acad. Sci. U.S.A.; 1986; 83(21); 8064 - 8068
Wester et	al, The Journal of Biological Chemistry, August 2004, Vol. 279, pp 35630-35637
*Examiner	Date Considered 1/24/01
Examiner: Initial if reference of Include copy of this form with it	onsidered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.  ext communication to application.  Form PTO-FB-A820 (Also PTO-1449)

- 6 -

### Sheet



INFORM	TAN	ION	DISCI	LOSU	RE
	_	T A -	TION		

(Use several sheets if necessary)

ATTY. DOCKET NO.

SERIAL NO.

CITATION

620-347

10/516,338

**COSME ET AL** 

FILING DATE

GROUP

November 30, 2004

Unassigned

EXAMINER	OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)
AR	Hutzler, et al., "Activation of cytochrome 2C9-mediated metabolism: mechanistic evidence in support of kinetic observation"; Archives of Biochemistry and Biophysics; 2003, 4 10, 16-24.
1	Hutzler, et al., "Activation Of CYP2C9-Mediated Metabolism By A Series Of Dapsone Analogs: Kinetics And Structural Requirements"; <i>Drug Metabolism and Disposition, 2002</i> , Vol 30, pp 1194-1200.
	Hutzler, et al. "Dansone Activation Of CYP2C9-Mediated Metabolism: Evidence For
(-	Activation Of Multiple Substrates And A Two-Site Model"; <i>Drug Metabolism and Disposition</i> , 2001, Vol 29, 1029-1034
	Korzekwa, et al., "Evaluation Of Atypical Cytochrome P450 Kinetics With Two-Substrate Models: Evidence That Multiple Substrate Can Bind Simultaneously Bind To Cytochrome P450 Active Sites"; <i>Biochemistry</i> ; 1998, Vol. 37, 4137-4147
	Melet, et al., "Substrate selectivity of human cytochrome P450 2C9: importance of residues 476,365, and 114 in recognition of diclofenac and sulfaphenazole and in mechanism-based inactivation by tienilic acid", Archives of Biochemistry and Biophysics, Volume 409, Issue I, I January 2003, Pages 80-91.
- ( - )	He, et al., "Structural forms of phenprocoumon and warfarin that are metabolized at the active site of CYP2C9"; Arch Biochem Biophys. 1999 Dee I;3 72(1):16-28.
	Kaminsky, et al. "Human P450 metabolism of warfarin"; Pharmacol Ther. 1997;73(1):67-74.
1	Kunze, et al., "Warfarin-fluconazole. I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: in vitro studies": <i>Drug Metab Dispos. 1996 Apr;24(4):414-</i> 21.
	Abstract 4, Johnson, et al., "Structural Characterization of Substrate and Inhibitor Binding to 2C P4505, The
	Abstract 5. Abstracts from 8th European ISSX Meeting (Monday 28th April 2003) Origin of Substrate Specificity of Cytochromes P450 2C": Chemical and Biochemical Approaches. <i>Daniel Mansuy, Universite Rene Descartes, Paris, France.</i>
	Abstract/Poster 77. Abstracts from 8th European ISSX Meeting (Monday 28th April 2003) Metabolism Prediction for Cytochrome P450. Isabel Zamora, Lead Molecular Design, XL. Sant Cugat de1 Valles, Spain.
	Abstract/Poster 81. Abstracts from 8th European ISSX Meeting (Monday 28th April 2003) Sulphenazole Derivatives as Tools for Comparing CYP 2C5 and Human 2C's: Identification of a New High Affinity Substrate (DMZ) Common to Those CYP 2C Enzymes. Patrick m. Dansette, Universite Rene Descartes, Paris, France.
	Marques-Soares, et al., "Sulfaphenazole Derivatives as Tools for Comparing Cytochrome P450 2C5 and Human Cytochromes P450 2Cs: Identification of a New High Affinity Substrate Common to Those Enzymes"; Biochemistry, 2003; 42(21): 6363-6369.
-	Wester, et al., "Structure of a Substrate Complex of Mammalian Cytochrome P450 2C5 at 2.3 A Hesolution: Evidence for Multiple Substrate Binding Modes": Biochemistry ; 2003; 42(21); 6370-6379.
	Zamora, et al., "Predicting Drug Metabolism: A Site of Metabolism Prediction Tool Applied to the Cytochrome P450 2C9": J. Med. Chem.: 2003: 46(12): 23 13-2324.
	Wester, et al., "Structure of Mammalian Cytochrome P450 2C5 Complexed with Diclotenac at 2.1 A  Resolution: Evidence for an Induced Fit Model of Substrate Binding"; Biochemistry; 2003; 42(3.1); 9335-9345
	Tsao, et al., "Identifiation of Human CYP2C19 Residues that Confer S-Mephenytoin 4'-Hydroxylation Activity to CYP2C9, Richard 2001: 40(7), 1937-1944
V	Longenecker, et al., "Protein crystallization by national mutagenesis of surface residues: Lys to Ala mutations promote crystallization of RhoGDI"; Acta Crystallogr D Bio Crystallogr; 2001, 57(Pt 5), 679-88.
*Examiner	Date Considered 194101
Examiner: Include cop	Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.  y of this form with next communication to application.
	y or this form with next communication to application.  Form PTO-FB-A820 (Also PTO-1445)

IN	INFORMATION DISCLOSURE CITATION		620-3			SERIAL NO. Unassign	ed 10/5	163	38	
		•			ME ET AL		•			<b>ω</b> 1/
	(	(Use s	several sheets if necessary)	FICINGU	AIE		GROUP			X
			_	Nove	mber 30, 20	04	Unassign	ed		
					J.S. PATENT [	OCUMENTS	-		EII INC	S DATE
'EXAMII			DOCUMENT NUMBER	DATE		NAME	CLAS	S SUBCLASS		OPRIATE
				:						
		1							ļ <u>.</u>	
		4-				<del></del>			<del> </del>	
		+							<del> </del>	
		╁				. <u> </u>				
		╁╴							<del> </del>	
		+			-				<b> </b>	
		†								
				FC	REIGN PATE	NT DOCUMENTS			TOANG	SLATION
			DOCUMENT	DATE		COUNTRY	CLAS	S SUBCLASS	YES	NO
		1						· · · · · · · · · · · · · · · · · · ·	<del>                                     </del>	<del> </del>
		_							<del>                                     </del>	<del>                                     </del>
		-						-	-	<del> </del>
	_	-							<del> </del>	
		+	<u> </u>					<del> .</del>		<del>                                     </del>
		+								1
			OTHER DOC	JMENTS (	including Aut	hor, Title, Date, Pe	rtinent page	es, etc.)		
	A!	7	Williams et al, Mole	cular Ce	II, January 2	2000, Vol. 5, No.	1, pp 121-	131		
	Ī		Von Wachenfeldt e 107-114	t al, Arch	ives of Bioc	hemistry and Bio	physics, 1	997, Vol. 33	19, No.	1, pp
			Cosme et al, Journa 2553	al of Biol	ogical Chem	nistry, January 28	3, 2000, Vo	ol. 275, No.	4, , pp	2545-
	1	1	Hasemann et al, Jo	urnal of	Molecular B	iology, 1994, Vol	. 236, No.	4, pp 1169-	1185	
	1		Lewis, Experimenta	al and To	xicologic Pa	thology, July 199	99, Vol. 51	, No. 4-5, pp	369-3	74
			Ibeanu et al, Journa 12501	al of Biol	ogical Chem	istry, May 24, 19	96, Vol. 2	71, No. 21, p	op 1249	96-
F	A	4	1.2001		<del> </del>					
*Exami	ne	r	/Alexander	Kim/		Date Considered	01	/24/2007		
			reference considered, whether or r	not citation is in	conformance with N	APEP 609; Draw line through			considered	Include
copy or th	10 E	iii Wl	th next communication to applicati	U11.				Form DTO ED	4000/41-	DTO 1440